| Primary |
| Bipolar Disorder |
22.2% |
| Schizoaffective Disorder |
17.5% |
| Depression |
9.5% |
| Anaesthesia |
6.3% |
| Bipolar I Disorder |
6.3% |
| Prophylaxis |
6.3% |
| Schizophrenia, Residual Type |
6.3% |
| Hypothyroidism |
3.2% |
| Mental Disorder |
3.2% |
| Sleep Disorder |
3.2% |
| Affect Lability |
1.6% |
| Bipolar Ii Disorder |
1.6% |
| Bronchitis |
1.6% |
| Cluster Headache |
1.6% |
| Fear |
1.6% |
| Hypertension |
1.6% |
| Major Depression |
1.6% |
| Osteoporosis |
1.6% |
| Psychotic Disorder |
1.6% |
| Restlessness |
1.6% |
|
| Vomiting |
19.2% |
| Suicide Attempt |
17.8% |
| Tremor |
15.1% |
| Renal Failure |
6.8% |
| Somnolence |
4.1% |
| Therapeutic Agent Toxicity |
4.1% |
| Atrioventricular Block First Degree |
2.7% |
| Drug Interaction |
2.7% |
| Psychotic Disorder |
2.7% |
| Restlessness |
2.7% |
| Sinoatrial Block |
2.7% |
| Sinus Bradycardia |
2.7% |
| Sluggishness |
2.7% |
| Syncope |
2.7% |
| Thrombocytopenia |
2.7% |
| Tooth Disorder |
2.7% |
| Akathisia |
1.4% |
| Fatigue |
1.4% |
| Gait Disturbance |
1.4% |
| Gamma-glutamyltransferase Increased |
1.4% |
|
| Secondary |
| Product Used For Unknown Indication |
42.8% |
| Drug Use For Unknown Indication |
22.8% |
| Depression |
6.9% |
| Obsessive-compulsive Disorder |
5.5% |
| Bipolar Disorder |
3.4% |
| Prophylaxis Of Neural Tube Defect |
3.4% |
| Schizoaffective Disorder |
3.4% |
| Hypertension |
2.8% |
| Atrial Fibrillation |
1.4% |
| Infertility Female |
1.4% |
| Type 2 Diabetes Mellitus |
1.4% |
| Abortion Threatened |
0.7% |
| Angiogram |
0.7% |
| Bipolar I Disorder |
0.7% |
| Hypothyroidism |
0.7% |
| Labour Induction |
0.7% |
| Thrombosis Prophylaxis |
0.7% |
| Vulvovaginal Mycotic Infection |
0.7% |
|
| Parkinsonism |
10.0% |
| Placental Disorder |
10.0% |
| Pneumonia |
10.0% |
| Suicide Attempt |
10.0% |
| Drug Interaction |
7.5% |
| Toxicity To Various Agents |
7.5% |
| Gait Disturbance |
5.0% |
| Residual Urine Volume Increased |
5.0% |
| Urinary Tract Infection |
5.0% |
| Weight Increased |
5.0% |
| Abortion Incomplete |
2.5% |
| Catatonia |
2.5% |
| Cognitive Disorder |
2.5% |
| Disorientation |
2.5% |
| Drug Exposure During Pregnancy |
2.5% |
| Leukopenia |
2.5% |
| Pleurothotonus |
2.5% |
| Rabbit Syndrome |
2.5% |
| Renal Failure Acute |
2.5% |
| Somnolence |
2.5% |
|
| Concomitant |
| Schizoaffective Disorder |
20.0% |
| Depression |
16.7% |
| Pain |
13.3% |
| Product Used For Unknown Indication |
10.0% |
| Bipolar Disorder |
6.7% |
| Hiv Infection |
6.7% |
| Prophylaxis |
6.7% |
| Sleep Disorder |
6.7% |
| Drug Level Changed |
3.3% |
| Dyssomnia |
3.3% |
| Extrapyramidal Disorder |
3.3% |
| Menorrhagia |
3.3% |
|
| Galactorrhoea |
25.0% |
| Tremor |
16.7% |
| Vomiting |
16.7% |
| Gait Disturbance |
8.3% |
| Gamma-glutamyltransferase Increased |
8.3% |
| Incontinence |
8.3% |
| Syncope |
8.3% |
| Thrombocytosis |
8.3% |
|
| Interacting |
| Drug Use For Unknown Indication |
66.7% |
| Ill-defined Disorder |
20.5% |
| Hypertension |
5.1% |
| Schizoaffective Disorder |
5.1% |
| Type 2 Diabetes Mellitus |
2.6% |
|
| Therapeutic Agent Toxicity |
50.0% |
| Pleurothotonus |
33.3% |
| Renal Failure Acute |
16.7% |
|
